Results 1 to 10 of about 1,925 (147)

Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids [PDF]

Respiratory Research, 2021
Background For patients with chronic obstructive pulmonary disease (COPD), greater improvements in lung function have been demonstrated for triple versus dual inhaled therapies in traditional spirometry studies. This study was the first to use functional
Maarten van den Berge, Jan De Backer, Cedric Van Holsbeke, Wilfried De Backer, Roopa Trivedi, Martin Jenkins, Paul Dorinsky, Magnus Aurivillius   +7 more
doaj   +6 more sources

Successful Sequential Treatment for Severe Asthma Coexisting COVID-19 via Budesonide/Glycopyrrolate/Formoterol Fumarate [PDF]

International Journal of General Medicine, 2021
Yingjian Liang,* Meizhu Chen,* Cuiyan Tan, Changli Tu, Xiaobin Zheng, Jing Liu Department of Pulmonary and Critical Care Medicine (PCCM), The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, People’s Republic of China*These authors ...
Yingjian Liang, Meizhu Chen, Cuiyan Tan   +2 more
exaly   +4 more sources

Effect of inhaled budesonide/formoterol fumarate dihydrate delivered via two different devices on lung function in patients with COPD and low peak inspiratory flow [PDF]

Therapeutic Advances in Respiratory Disease, 2022
Background and aims: Low peak inspiratory flow (PIF) is common following severe exacerbations of chronic obstructive pulmonary disease (COPD). Patients with COPD and low PIF may be at risk of suboptimal delivery of inhaled therapies to the airways ...
Bärbel Huber, Claus Keller, Martin Jenkins, Abid Raza, Magnus Aurivillius   +4 more
doaj   +2 more sources

Cost-Effectiveness of Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: United Kingdom Analysis Using the ETHOS Study [PDF]

International Journal of COPD, 2022
Enrico de Nigris,1 Catrin Treharne,2 Nick Brighton,2 Ulf Holmgren,3 Andrew Walker,4 John Haughney5 1Formerly of Global Product and Portfolio Strategy, AstraZeneca, Cambridge, UK; 2Formerly of Health Economic Modelling, Regulatory and Access, Parexel ...
de Nigris E, Treharne C, Brighton N, Holmgren U, Walker A, Haughney J   +5 more
doaj   +2 more sources

Effect of budesonide/glycopyrronium/formoterol fumarate dihydrate on cardiopulmonary outcomes in COPD: rationale and design of the THARROS trial [PDF]

ERJ Open Research
Background COPD and cardiovascular disease (CVD) are leading causes of death with overlapping and syndemic pathophysiological interactions. Inhaled triple therapies containing inhaled corticosteroids (ICS), long-acting muscarinic antagonists (LAMA) and ...
Fernando J. Martinez, John R. Hurst, MeiLan K. Han, David Price, Jinping Zheng, David D. Berg, Michel Pszczol, Mona Bafadhel, Carolyn S.P. Lam, Martin Fredriksson, Martin R. Cowie, Niki Arya, Karin Bowen, Alec Mushunje, Mehul Patel   +14 more
doaj   +2 more sources

Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies for Patients with COPD and Phenotypic Features of Asthma: A Pooled Post Hoc Analysis of KRONOS and ETHOS [PDF]

International Journal of COPD
Shigeo Muro,1 Munehiro Seki,2 John R Hurst,3 David Petullo,4 Jonathan Marshall,5 Karin Bowen,4 Patrick F Darken,4 Elizabeth A Duncan,6 Ayman Megally,4 Mehul Patel5 1Department of Respiratory Medicine, Nara Medical University, Nara, Japan; 2AstraZeneca K ...
Muro S, Seki M, Hurst JR, Petullo D, Marshall J, Bowen K, Darken PF, Duncan EA, Megally A, Patel M   +9 more
doaj   +2 more sources

Efficacy of fluticasone propionate/formoterol fumarate in the treatment of asthma: A pooled analysis [PDF]

Respiratory Medicine, 2015
Fluticasone propionate and formoterol fumarate have been combined in a single inhaler (fluticasone/formoterol; flutiform(®)) for the maintenance treatment of asthma. This pooled analysis assessed the efficacy of fluticasone/formoterol versus fluticasone in patients who previously received inhaled corticosteroids.Data were pooled from five randomised ...
Alberto Papi, David Price, Joaquin Sastre   +2 more
exaly   +3 more sources

Evaluating Arrhythmia Risk in Patients with Chronic Obstructive Pulmonary Disease Treated with Aclidinium/Formoterol Fumarate and Other Inhaled Bronchodilators: A Post-Authorization Safety Study [PDF]

International Journal of COPD
Cristina Rebordosa,1 Jaume Aguado,1 Jennifer Bartsch,2 Nuria Saigi-Morgui,1 Anne-Elie Carsin,1 Raquel Garcia-Esteban,1 Elena Ignatova,3 Daniel Freedman,3 Susana Perez-Gutthann,1 Elena Rivero-Ferrer1 1RTI Health Solutions, Barcelona, Spain; 2RTI Health ...
Rebordosa C, Aguado J, Bartsch J, Saigi-Morgui N, Carsin AE, Garcia-Esteban R, Ignatova E, Freedman D, Perez-Gutthann S, Rivero-Ferrer E   +9 more
doaj   +2 more sources

Pharmacokinetics of extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide in adolescent and adult patients with asthma [PDF]

Pharmacology Research & Perspectives, 2022
The single‐inhaler extrafine formulation triple combination beclometasone dipropionate (BDP), formoterol fumarate (FF) plus glycopyrronium bromide (GB) is available for asthma management in adults. Its use in adolescents has not yet been evaluated.
Piotr Kuna, Joanna Jerzynska, Matteo Martini, Andrea Vele, Irene Barneschi, Fabrizia Mariotti, George Georges, Giorgia Ciurlia   +7 more
doaj   +2 more sources

Efficacy and safety of fluticasone propionate/formoterol fumarate in pediatric asthma patients: a randomized controlled trial

Therapeutic Advances in Respiratory Disease, 2018
Background: The efficacy and safety of fluticasone propionate/formoterol fumarate pressurized metered-dose inhaler (pMDI) (fluticasone/formoterol; Flutiform ® ; 100/10 µg b.i.d.) was compared with fluticasone propionate (Flixotide ® Evohaler ® pMDI; 100 ...
Sanjeeva Dissanayake
exaly   +2 more sources